Hybridoma technology: a view from the patent arena

The patenting of biological molecules, such as hybridomas and monoclonal antibodies, has become an important issue in biology. While challenging cherished beliefs and practices of many biologists, it has been a central issue for hybridoma and monoclonal antibody research.